Skip to main content
Lexeo Therapeutics, Inc. logo

Lexeo Therapeutics, Inc. — Investor Relations & Filings

Ticker · LXEO ISIN · US52886X1072 US Manufacturing
Open in API
Filings indexed 289 across all filing types
Latest filing 2022-05-05 Regulatory Filings
Country US United States of America
Listing US LXEO

About Lexeo Therapeutics, Inc.

https://www.lexeotx.com/

Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to developing gene therapies for genetically defined diseases. The company is advancing a diverse pipeline of investigational adeno-associated virus (AAV)-based gene therapy candidates. Its primary areas of focus are rare cardiovascular diseases and APOE4-associated Alzheimer's disease. Lexeo's strategy centers on addressing conditions with high unmet medical needs by leveraging pioneering science, including research originating from institutions such as Weill Cornell Medicine, to develop treatments with curative potential.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a detailed response letter from a company to the U.S. Securities and Exchange Commission (SEC) staff regarding comments on a Draft Registration Statement on Form S-1. It discusses amendments to the registration statement, clinical trial phases, intellectual property, agreements, and other disclosures related to an IPO filing. The presence of detailed responses to SEC comments on a Form S-1 registration statement, including references to amendments and exhibits, clearly identifies this as a regulatory filing related to the IPO process. It is not a financial report, earnings release, or other types of filings listed. The document is lengthy (15,000 characters) and contains substantive content, not just an announcement or certification. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2022-05-05 English
Capital/Financing Update 2022
Capital/Financing Update Classification · 95% confidence The document is an Amendment No. 1 to a draft registration statement on Form S-1 filed confidentially with the SEC by Lexeo Therapeutics, Inc. It is a preliminary prospectus for an initial public offering (IPO) of common stock. The document includes detailed information typical of an S-1 registration statement such as risk factors, use of proceeds, capitalization, management discussion and analysis, business overview, management, executive compensation, principal stockholders, and financial statements. This type of filing is a registration statement for securities offering, which is a capital raising activity. According to the filing definitions, updates on company fundraising or financing activities fall under Capital/Financing Update (CAP). The document is not an annual report, earnings release, or other report types but a registration statement related to capital raising. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed information, not just an announcement or notice, supporting a high confidence score.
2022-05-05 English
Regulatory Filings 2022
Regulatory Filings
2022-03-03 English
Capital/Financing Update 2022
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed confidentially with the SEC by Lexeo Therapeutics, Inc. It is a preliminary prospectus for an initial public offering (IPO) of common stock. The text includes detailed information about the offering, company overview, risk factors, management discussion, financial condition, and other disclosures typical of an IPO registration statement. This type of filing is related to capital raising and financing activities, specifically the registration of securities for public sale. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document is not an annual or quarterly report, audit report, earnings release, or any other category defined in the list. It is a registration statement for a securities offering, which is a capital market activity.
2022-02-04 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.